Chinese Pharma Stocks Rebound From Lows; Xiangrikui Hits 20% Limit Up

The breadth of the rebound — spanning multiple small- and mid-cap names rather than a single bellwether — suggests a sector-wide sentiment shift rather than stock-specific news. The common thread is the daily limit mechanism itself, which caps upside and can amplify momentum once triggered. Whether the rally holds past the limit-up names, or fades as the broader pharma group digests the move, is the open question worth watching.